Детекция и мониторинг клональных перестроек генов тяжелых цепей иммуноглобулинов у больных множественной миеломой
Диссертация
В ходе терапии множественной миеломы молекулярный маркер опухоли в образцах периферической крови перестает обнаруживаться значительно раньше, чем в костном мозге, поэтому для мониторинга минимальной резидуальной болезни целесообразно использовать образцы костного мозга. Кпональная реаранжировка генов тяжелых цепей иммуноглобулинов выявлена у 90% больных парапротеинемическими гемобластозами… Читать ещё >
Содержание
- Список используемых сокращений
- Глава 1. Обзор литературы
- Глава 2. Материалы и методы исследования
- 2. 1. Характеристика больных
- 2. 2. Программы химиотерапии, используемые у больных ММ
- 2. 3. Методы исследования
- 2. 4. Статистический анализ полученных данных
- 2. 5. Основные понятия
- Глава 3. Результаты и их обсуждение
- 3. 1. Результаты клинического исследования
- 3. 2. Результаты детекции реаранжировок генов IgH
- 3. 3. Мониторинг минимальной резидуальной болезни
- 3. 4. Результаты и обсуждение статистического анализа
Список литературы
- Абелев Г. И. Механизмы дифференцировки и опухолевый рост. Биохимия 2000, 65, 127−13.
- Айала Ф.Дж., Кигер Дж.А. Современная генетика. 1988- т. 1. Изд. Мир, Москва.
- Андреева Н.Е. Вялотекущая множественная миелома. Проблемы гематологии 1983- 4: 55−58.
- Андреева Н.Е., Чернохвостова Е. В. Иммуноглобулинопатии. М.: Медицина 1985
- Андреева Н.Е. Диагностика и лечение множественной миеломы. М. Ньюамед-АО 1998.
- Андреева Н.Е. Парапротеинемические гемобластозы. Руководство по гематологии под редакцией А. И. Воробьева. М.: Медицина, 1985- 290−313.
- Албертс Б., Брей Д., Льюис Дж. и др. Молекулярная биология клетки. Изд. Мир, 1994, том 3, 465−481.
- Барышников А.Ю. Программированная клеточная смерть (апоптоз). Клиническая онкогематология под редакцией М. А. Волковой. Изд. Медицина 2001, глава 4, 36−41.
- Воробьев А.И. Общий патогенез гемобластозов. Руководство по гематологии, том 1, с. 147−150.
- Кондратенко И.В. Клеточные основы иммунного ответа. Вопросы гематологии, онкологии и иммунопатологии в педиатрии. 2003- 3: 71−78.
- Кузнецов С.В. Апоптоз и некоторые механизмы его регуляции. Проблемы гематологии, 1998- 2: 22−27.
- Мелешко А.Н., Потапнев М. П. Оценка реаранжировки генов иммуноглобулинов и Т-клеточного рецептора при лимфопролиферативных заболеваниях: методология и клиническое значение. Гематология и трансфузиология 2006- 2: 34−41.
- Никитин Е.А., Ленива Е. А., Судариков А. Б. Роль молекулярных методов в диагностике и мониторинге лимфопролиферативных заболеваний. Гематология и трансфузиология 2001- 3: 19−26.
- Никитин Е.А., Пивник А. В., Судариков А. Б. Сравнение форм хронического лимфолейкоза в зависимости от мутационного статуса генов вариабельного региона иммуноглобулинов. Тер. архив 2000- 7: 52−56.
- Татосян А.Г., Зуева Э. Ш. Механизмы активации онкогенов. Клиническая онкогематология под редакцией М. А. Волковой. Изд. Медицина 2001, глава 2, 22−28.
- Цикалов В.А., Журавлев С. В., Мокеева Р. А., Козинец Г. И. Клиническое значение иследования пролиферативной активности плазматических клеток при множественной миеломе. Проблемы гематологии 1983- 4: 36−40.
- Aktan М., Akkaya A., Dogan О. Chronic lymphocytic leukemia and multiple myeloma in the same patient: case report. Leuk. Lymphoma 2003- 44: 1421−1424.
- Alexanian R., Bonnet J., Gehan E., et al. Combination chemotherapy for multiple myeloma. Cancer 1972- 30: 382−389.
- Alexanian R., Haut A., Khan A. Treatment of multiple myeloma: Combination therapy with different melphalan dose regiments. J. Am. Med. Assoc. 1969- 208:1680−1685
- Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N. Engl. J. Med. 1994- 330:484−489.
- Alexanian R., Barlogie В., Tucker S., et al. VAD-based regimens as primary treatment for multiple mueloma. 1990- 33: 86−89.
- Alexanian R., Dimopoulos M., Smith T. Limited value of myeloblative therapy for late myeloma. Blood, 1994- 83: 512−516.
- Alexanian R., Barlogie В., Tucker S., et al. VAD-based regimens as primary treatment for multiple mueloma. 1990- 33: 86−89.
- Alt F.W., Oltz E.M., Young F., et al. VDJ recombination. Immunol. Today 1992- 13: 306−313.
- Anderson K.C., Lust J.A. Role of cytokines in multiple myeloma. Semin. Hematolog. 1999- 36: 14−20.
- Ashcroft J., Rawstron A.C., Owen R.G., et al. Penotyping in myeloma: identification of a rare CD19+56 -subgroup. Blood 2000- 96: 156a.
- Attal M., Harousseau J.L., Facon Т., et al. Single versus double transplantation in myeloma: a prospective randomized trial of Intergroupe Francophone du Myeloma. Blood 2000- 96: 557a.
- Attal M., Harousseau J-L., Stoppa A-M. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med. 1996- 335: 91−97.
- Attal M., Harousseau J.L. Autologous transplantation in multiple myeloma. Gahrton G., Durie B.G.M., Arnold, London, 1996, 182.
- Avet-Loiseau H., Gerson F., Magrangeas F., et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001- 98: 3082−3086.
- Avet-Loiseau H., Daviet A., Sauner S., et al. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br. Journal of Haematol. 2000- 111: 1116−1117.
- Avet-Loiseau H. Genetics of multiple myeloma. Haematology 2005- 1: 206−210.
- Bahler D.W., Campbell M.J., Hart S. lg VH gene expression among human follicular lymphoma. Blood 1991- 78: 1561−1668.
- Bakkus M.H.C., Van-Rirt I., et al. Evidence that the clonogenic cell in multiple myeloma originates from pre-switched but somatically mutated B-cell. Br.J.Haematol. 1994- 87: 68−74.
- Bakkus M.H., Heirman C., Van-Rirt I., et al. Evidence that multiple myeloma lg heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992- 80: 2326−2335.
- Bakkus M.H.C., Bouko J., Samson D., et al. Post-transplantation tumor load in bone marrow, as assessed by quatitative ASO-PCR, is a prognostic parameter in multiple myeloma abstract. Br. J. Haematol. 2004- 126: 665.
- Barlogie В., Alexanian R., Dicke K.A. et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistans multiple myeloma. Blood 1987- 70: 869−872.
- Barlogie В., Jagannath S., Desican K.R.: Total Therapy with Tandem Transplants for Newly Diagnosed Multiple Myeloma. Blood 1999- 93: 55−65.
- Barlogie В., Spencer Т., Tricot G., et al. Long term follow-up of 169 patients receiving a phase II trial of singl agent thalidomide for advanced and refractory multiple myeloma. Blood 2000- 96: 514a.
- Barlogie В., Shaughnessy J., Tricot G., et al. Treatment of multiple myeloma. Blood 2004- 103: 20−32.
- Barton J.C. Thalidomide and dexamethasone therapy of myeloma in a patient with previously untreated B-chronic lymphocytic leukemia. Am. J. Hematol. 2003- 74: 205 207.
- Bataille R., Durie B.G.M., Grenier J., et al. Serum p2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br. J Hematol. 1983- 55:439−447.
- Bataille R., Grenier J., Sany J. Beta-2-microglobulin in myeloma: Optimal using in staging, prognosis and threatment. Blood 1984- 63: 472−476.
- Bataille R., Boccadoro M., Klein B. C-reactive protein and beta-2-microglobulin produce a simple and powerful myeloma staging system. Blood 1992- 80: 733−737.
- Billadeau D., Quam L., Thomas W., et al. Detection and quantitation of malignant cells in peripheral blood of multiple myeloma patients. 1992- 7: 1818−1824.
- Billadeau D., Blackstadt M., Greipp P. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual didease. Blood 1991- 78: 3021−3029.
- Bensinger W.I., Buckner C.D., Anasetti C., et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996- 88: 27 872 793.
- Bensinger W.I., Buckner D., Gahrton G. Allogeneic stem cell transplantation for multiple myeloma. Hematol. Oncol. Clin. Norf. Am. 1997- 11: 147−157.
- Bergel F., Stock J.A. Ann. Rep. Brit. Emp. Cancer. Comparign. 1953- 31: 607.
- Bergsagel D.E., Wong O., Bergsagel P.L.: Benzene and multiple myeloma: appraisal of scientific evidence. Blood 1999- 94: 1174−1182.
- Bergsagel P.L., Kuehi W.M. Chromosome translocations in multiple myeloma. Oncogene 2001- 20: 5611−5622.
- Bergsagel P.L., Kuehl W.M. Crinical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol. Rev. 2003- 194: 96−104.
- Bergsagel D.E., Sprague C.C., Austin C., et al. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma: IV. L-Phenylalanin mustard (NC-8806) Cancer Chemoter. Rep. 1962- 21: 87−99.
- Bezieau S., Aver-Loiseau H., Moisan J.P., et al. Activating Ras mutations in patients with plasma-cell disorders: a reappraisal. Blood 2003- 100: 1101−1102.
- Blade J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Br. J. Haematol. 1998- 102: 1115−1123.
- Blokhin N.N., et al. Clinical experiences with sarcolysin in neoplastic diseases. Ann. NY Acad. Sci. 1958- 68: 1128−1132.
- Brisco M.J., Tan L.W., Orsborn A.M. Development of a highly sensitive assay, based on the polymerase chain reaction, for rare B-Iimphocyte clones in a polyclonal population. Br. J. Haematol. 1990- 75: 163−167.
- Browman G.P., Bergsagel D., Sicheri D., et al. Randomized trial of interferon maintenance in multiple myeloma. A study of the National Cancer Institute of Canada, Clinical Trials Group. J. Clin. Oncol. 1995- 13: 2354.
- Carlo-Stella C., Mangon L., Potti G.P. Techniques for detection minimal residual disease. Leukemia and Lymph. 1995- 18: 75−80.
- Castryck H., Van Den Driessche M., Hagemeijer A. Coexistence of light chain disease and lymphocytic leukemia, a complex karyotype with a rapid fatal outcome. Clin. Lab. Haematol. 2006- 28: 138−140.
- Cavo M., Galieni P., Zuffa E., et al. Prognostic variables and clinical staging in multiple myeloma. Blood 1989- 74: 1774−1780.
- Cavo M., Terragna C., Martinelli G., et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 2000- 96: 355−357.
- Cavo M., Cellini C., Zamagni E., et al. Superiority of double over single autologous stem cell transplantation as first-line therapy for multiple myeloma. Blood 2004- 103: 155a (abstr.)
- Cavo M., Zamagni E., Tosi P., et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004- 89: 826−831.
- Chiecchio L., Protheroe R.C., Ibrahim A.H., et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006- 20: 1610−1617.
- Child J., Morgan G., Davies f., et al. High-dose therapy with hematopoietic stem cell transplantation for multiple myeloma. N. Engl. J. Med. 2003- 348: 1875−1883.
- Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with haematopoietic stem cell rescue for multiple myeloma. N. Engl. J. Med. 1996- 384: 1875−1883.
- Chronic Leukemia-Myeloma Task Force National Cancer Institute. Proposed guidelines for protocol studies. II Plasma cell myeloma. Cancer Chemother. Rep. 1973- 4: 145−157.
- Cigudosa J.C., Rao P.H., Calasanz M.J., et al. Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood 1998- 91: 3007−3010.
- Ciudad J., San Miguel J.F., Lopez-Berges M.C. et al. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J. Clin. Oncol. 1998- 16: 3774−3781.
- Cook G.P., Tomlinson I.M. The human immunoglobulin VH repertore. Immunol. Today 1995- 16: 237−242.
- Cook G.P., Tomlinson I.M., Walter G., et al. A map of the human immunoglobulin VH locus completed by analysis of the telomeric region of chromosome 14q. Nature Genet. 1994- 7: 162−170.
- Corradini P., Cavo M., Lokhorst H., et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003- 102: 1927−1929.
- Corradini P., Voena C., Tarella C., et al. Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells. J. of Clinic. Oncology 1999- 17: 208−215.
- Corradini P., Voena C., Astolfi M., et al. High-dose Sequential Chemoradiotherapy in Multiple Myeloma: Residual Tumor Cells are Detectable in Bone Marrow and Peripheral Blood Cell Harvests and After Autografting. Blood 1995- 85: 1596−1602.
- D’Amato R.J., Loughnan M.S., Flynn E. & Folkman J. Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of the USA. 1994- 91: 40 824 085.
- Davies F.E., Raje N., Hideshima Т., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001- 98: 210−216.
- Dewald G., Therneau Т., Larson D., et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis myeloma. Blood 2005- 106: 3553−3558.
- Dewald G., Kyle R., Hicks G., et al. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukaemia or amyloidosis. Blood 1985- 66: 380−390.
- Dewald G., Therneau Т., Larson D., et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis myeloma. Blood 2005- 106: 3553−3558
- Deanne M.D., Norton J.D. Immunoglobulin heavy chain variable region family usage is independent of tumor cell phenotype in human В lineage leukemias. Eur. J. Immunol. 1990- 20: 2209−2217/
- Dimopoulos M.A., Anagnostopoulos A., Terpos E. Novel drugs in the treatment of multiple myeloma. Hematology 2005- 1: 211−215. :
- Dolken G. Detection of minimal residual disease. Adv. Cancer Res. 2001- 82: 133 185.
- Drach J., Angerler J., Schuster J., et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 1995- 86: 3915−3921.
- Drach J., Ackermann J., Fritz E., et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after the conventional-dose chemotherapy. Blood 1998- 92: 802−809.
- Drach J., Sagaster V., Ackerman J., et al. Prognostic factors for multiple myeloma. Haematol. 2006- 2: 196−200.
- Duke V. M, Gandini D., Sherrington P.D. VH gene usage differs in gemline and mutated B-cell chronic lymphocytic leukemia. Haematologica 2003- 88: 1259−71/
- Durie B.G.M., Salmon S.E. Clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975- 36: 842.
- Dune B.G.M., Salmon S.E., Moon Т.Е.: Blood 1980- 55: 364−372.
- Durie B.G.M., Stock-Novack D., Salmon S.E. Prognostic value of pretreatment serum 32-microglobulin in myeloma: Southwest Oncology Group Study. Blood 1990- 75:823−830.
- Durie B.G., Harousseau J.-L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006- 20:1467−1473.
- Fassas A.B.-T., Spencer Т., Sawyer J., et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br. J. Haematol. 2002- 118: 1041−1047.
- Fenk R., Ak M., Kobbe G., et al. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma. Hematologica 2004- 89: 557−565.
- Fonseca R., Harrington D., Oken M. Prognostic significance of 13q deletions and t (11−14)(q13-q32) in myeloma: an interphase FISH study of 351 patients entered into the Eastern Oncology Group E9487 clinical trial. Blood 2000- 96: 547a.
- Fonseca R., Blood E., Greipp P. Myeloma and the t (11−14)(q13-q32) — evidence for biologically defined unique subset of patients. Blood 2002- 99: 3735−3746.
- Fonseca R., Biley R.J., Ahmann G.J. et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002- 100: 1417−1424.
- Fonseca R., Blood E., Rue M., et al. Clinican and biologic implications of recurrent genomic aberration in myeloma. Blood 2003- 101: 4569−4575.
- Fonseca R., Debes-Marun C.S., Picken E.B., et al. The recurrent IgH translocations are highly associated with nonhyperdiploid varian multiple myeloma. Blood 2003- 102: 2562−2567.
- Gahrton G. Allogeneic stem cell transplantation in multiple myeloma-an update of EBMT regisry. VI International Workshop on Multiple Myeloma. Boston- USA 1997.
- Gahrton G. Allogeneic bone marrow transplantation in multiple myeloma. Pathol. Biol. 1999- 47: 188−191.
- Galimberti S., Morabito F., Guerrini F., et al. Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Br. J. Haematol. 2003- 120: 405−412.
- Galimberti S., Benedetti E., Morabito F., et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Leuk. Res. 2005- 29: 961−966.
- Gonzalez D., Gonzales M., Balanzategui A. Molecular characteristics and gene segment usage in IGH gene rearrangements in multiple myeloma. The Hematology J. 2005- 90: 906−913.
- Gore M.E., Selby P.J., Viner C., et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lanset 1989- II: 879−881.
- Gould J., Alexanian R., Goodacre A., et al. Plasma cell karyotype in multiple myeloma. Blood 1988- 7: 453−456.
- Greipp P.R., Lust J.A., O’Fallon M. Plasma cell labeling index and p2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993- 81: 3382.
- Greipp R.R., San Miguel J.F., Fonseca R., et al. Development of an International Prognostic Index (IPI) for myeloma: report of the International Myeloma Working Group. Haematol. J. 2003- 4: p 7.1, 43−44.
- Greipp R.R., San Miguel J.F., Durie B.G.M., et al. International Staging System for multiple myeloma. J. Clin. Oncolog. 2005- 23: 3412−3420.
- Gregory W.M., Richards M.A., Malpas J.S., et al. Combination chemotherapy versus melphalan and prednisolon in the treatment of multiple myeloma. An overview of published trials. J. Clin. Oncol. 1992- 10: 334−342.
- Hadzidimitriou A., Stamatopoulos K., Belessi C. Immunoglobulin genes in multiple myeloma: expressed and non-expressed repertoires, heavy and light chain pairings and somatic mutation patterns in a series of 101 cases. Haematologica 2006- 91: 781−787.
- Hayashi Т., Hideshima Т., Anderson K.C. Novel therapies for multiple myeloma. Review. Br. J. Haematolog. 2003- 120: 10−17.
- Hellek M., Bersagel P.L., Anderson K. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998- 91: 3−21.
- Hideshima Т., Bergsagel P.L., Kuehl W.M., Anderson K.C. Advances in biology of multiple myeloma: clinical applications. Blood 2004- 104: 607−618.
- Hideshima Т., Chauhan D., Shima Y., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000- 96: 2943−2950.
- Hsu F.J., levy R. Preferential use of VH4 lg gene family by diffuse large-cell lymphoma. Blood 1995- 86: 3072−3082.
- Jacobson J., Hussein M., Barlogie B. A new staging system for multiple myeloma patients based on the southwest Oncology Group (SWOG) experience. Br. J. Haematol. 2003- 122: 441−450.
- Jagannath S., Vesole D.H., Glenn L., Crowley J., et al. Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992- 80: 1666−1672.
- Janssen J.W., Vaandrager J.W., Heuser Т., et al. Concurreent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t (11−14)(q13-q32). Blood 2000- 95: 2691−2698.
- Joy P.H. Chromosomal and genetic abnormalities in myeloma. Clin. Lab. Haem. 2002- 24: 259−269.
- Juge-Morineau N., Harousseau J.L., Amoit M., et al. The retinoblastoma susceptibility gene RB1 in multiple myeloma. Leuk.&Lymph. 1997- 24: 229−237.
- Kaufmann H., Urbauer E., Ackermann J., et al. Advances in biology and therapeutic management of multiple myeloma. Ann. Hematol. 2001- 80: 445−451.
- Kaufmann H., Ackermann J., Nosslinger T. Absence of clonal chromosomal relationship between concomitant B-CLL and multiple myeloma a report on two cases. Ann Hematol. 2001- 80: 474−478.
- Kaufman J., Lonial S. Multiple myeloma: the role of transplant and novel treatment strategies. Seminars in Oncology 2004- 31: 99−105.
- Keats J.J., Reiman Т., Maxwell C.A., et al. In multiple myeloma t (4−14)(p16-q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003- 101: 1520−1529.
- Klein В., Zhang X.G., Lu Z.I., et al. lnterleukin-6 in human multiple myeloma. Blood 1995- 85: 863−872.
- Konigsberg R., Zojer N., Ackermann J. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J. Clin. Oncol. 2000- 18: 804−812.
- Korst D.R., Clifford G.O., Fowler W.M. J. Am. Med. Assoc. 1964- 83: 535−538.
- Kuehl W.M., Bergsagel P.L. Multiple myeloma: evolving genetic events and horst interactions. Rev. Cancer. 2002- 2: 175−187.
- Kyle R.A.: Multiple Myeloma: An Overview in 1996. The Oncologist 1996- 1: 315 323.
- Kyle R.A. Update on Treatment of Multiple Myeloma. The Oncologist 2001- 6: 119 124.
- Kyle R.A., Child J.A., Durie B.G.M. Criteria for the classification of monoclonal gammapathies, multiple myeloma, and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol. 2003- 121: 749−757.
- Lai J.L., Zandeski M., Mary G., et al. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 1995- 85: 24 902 497.
- Larionov L.F., Shkodinskaja E.N., Troosheikina V.I. Lancet. 1955- 2: 169−171.
- Lee G.C., Hong J.S., Lee K.H. A case of coincident multiple myeloma and non-Hodgkin"s lymphoma. Korean J. Intern. Med. 1994- 9: 113−115 (abstr.).
- Lida S., Rao P.H., Butler M., et al. Deregulation of MUM1/IFR4 by chromosomal translocation in multiple myeloma. Nat. Genet. 1997- 17: 226−230.
- Lipinski E., Cremer F.W., Ho A.D.: Molecular monitoring of the tumor load predicts progressive disease with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2001- 28, 957 962.
- Macaluso M., Montanari M., Cinti С., et al. Modulation of cell cycle components by epigenetic and genetic events. Semin. Oncolog. 2005- 32: 452−457.
- Malpas J.S., Bergsagel P.L., Kyle R., et al. Myeloma. Biology and management. 3rd Ed. Newcastle 2004- 163−194.
- Mandelli F., Awisati G., Amadori S. et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N. Engl. J. Med. 322: 1430.
- Martinelli G., Terragna C., Zamagni E. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. Haematologica 2000- 85: 930−934.
- McElwain T.J., Powles R.L. High-dose intravenous melphalan for plasma-cell leukemia and myeloma. Lancet 1983- 1: 822−824.
- Myeloma Trialists Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J. Clin. Oncol. 1998- 16: 3832−3842.
- Myeloma Trialists Collaborative Group. Interferon as therapy for multiple myeloma: an individual patients data overview of 24 randomized trials and 4012 patients. Br. J. Haematol. 2001- 113: 1020−1034.
- Mughal T.I., Yong A., Szydlo R.M. et al. Molecular studies in patients with chronic myeloid leukemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br. J. Haematol. 2001- 115: 569−574.
- Nevins J.R., Leone G., DeGregori J., et al. Role of the Rb/E2 °F pathway in cell growth control. J. Cell Physiol. 1997- 173: 233−236.
- Pelliniemi T.T., Irjala K., Mattila K. Immunoreactive interleukin-6 and acude phase proteins as prognostic factors in multiple myeloma. Blood 1995- 85: 765−771.
- Perez-Simon J.A., Garcia-Sanz R., Tabernere M.D., et al. Prognostic value of numerical chromosomal aberrations in multiple myeloma: a FISH analysis of 15 different chromosoms. Blood 1998- 91: 3366−3371.
- Preudhomme C., Facon Т., Zandeski M., et al. Rare occurrence of p53 gene mutations in multiple myeloma. Br. J. Haematol. 1992- 81: 440−443.
- Raab M.S., Cremer F.W., Breitkreutz I.N., et al. Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Ann. Oncol. 2005- 16: 611−617.
- Ralph Q.M., Brisco M.J., Joshua D.E. Advancement of multiple myeloma lg heavy chain gene from diagnosis through plateau phase to progression does not involve a new B-cell clone: evidence from the lg heavy chain gene. Blood 1993- 82: 202−206.
- Rao S.P., Riggs J.M., Biased VH gene usage in early lineage human В cells: avidence for preferential lg gene rearrangement in the absence of selection. J. Immunol. 1999- 163: 2732−2740.
- Reiman Т., Seeberger K., Taylor B.J., et al. Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone. Blood 2001- 98: 2791−2799.
- Rettig M.B., Vescio R.A., Cao G. VH gene usage in multiple myeloma: complete absence of the VH4.21 (VH4−34) gene. Blood 1996- 87: 2846−2852.
- Richelda R., Ronchetti D., Baldini L., et al. A novel chromosomal translocation t (4−14)(p16-q32) in multiple myeloma involves fibroblast growth-factor receptor 3 gene. Blood 1997- 90: 4062−4070.
- Richardson P.G., Barlogie В., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003- 348: 2609−2617.
- Sahota S., Leo R., Hamblin T.J. Myeloma V L and VH Gene Sequences Reveal a Complementary Imprint of Antigen Selection in Tumor Cells. Blood 1997- 89: 219 226.
- Saltman D.L., Ross J.A., Banks R.E. Molecular evidence for single clonal origin in biphenotypic concomitant chronic lymphocytic leukemia and multiple myeloma. Blood 1989−74:2062−2065.
- Samson D., Gaminara E., Newland A., et al. Infusion of vincristine and doxorubicin with oral dexametasone as first-line therapy multiple mueloma. Lancet 1989- 2: 882 885.
- Sanz I., Kelly P., Williams C., et al. The smaller human Vh gene families display remarkably little polymorphism. EMBO J. 1989- 8: 3741−3747.
- San Miguel J.F., Almeida J., Mateo G., et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 2002- 99: 1853−1855.
- San-Miguel J.F., Gutierrez N., Garcia-Sanz R., et al. Thalidomide and new drugs for treatment of multiple myeloma. Hematol. J. 2003- 4 (suppl.3): 201−207.
- Schatz D.G., Oettinger M.A., Schlissel M.S. V (D)J recombination: molecular biology and regulation. Ann. Rev. Immunol. 1992- 10- 359−383.
- Shaughnessy J., Gabrea A., Qi Y., et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations in immunoglobulin loci in multiple myeloma. Blood 2001- 98: 217−223.
- Shaughnessy J., Tian E., Sawyer J., et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 2000- 96: 1505−1511.
- Shou Y., Martelli M.L., Gabrea A., et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc. Natl. Acad. Sci. USA 2000- 97: 228−233.
- Singhal S., Mehta J., Desikan R. Et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 1999- 341: 1565−1571.
- Smadja N.V., Bastard C., Brigaudeau C., et al. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001- 98: 2229−2238.
- Spom JR, Mclntyre OR. Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results. Semin. Oncol. 1986- 13: 318−325.
- Steensma D.P., Gertz M.A., Greipp P.R. et al. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is marker for early disease progression and death. Blood 2001- 97: 2522−2523.
- Stewart A.K., Schwartz R.S. Immunoglobulin V region and В cell. Blood 1994- 83: 1717−1730.
- Sucker C., Kramer A., Moos M. Concomitant chronic lymphocytic leukemia and multiple myeloma: proof of common clonal origin. The Chinese-German J. of Clinical Oncol. 2004- 3: 81−84.
- Suzuki I., Pfister L., Annuska G., et al. Representation of rearranged VH gene segments in the human adult antibody repertoire. J. Immunol. 1995- 154: 3902.
- Swedin A., Lenhoff S.(Olofsson Т., et al. Clinical utility of immunoglobulin heavy chain gene rearrangement identification for tumour cell detection in multiple myeloma. Blood 2000- 96: 355−357.
- Terpos E., Eleutherakis-Papaiakovos V., Dimopoulos M.A. Clinical implications of chromosomal abnormalities in multiple myeloma. Leuk. & Lymph. 2006- 47: 803 814.
- The Nordic Myeloma Study Group. Interferon alpha 2b added to melphalan prednisone for initial and maintenance treatment in multiple myeloma. Ann. Inter. Med. 1996- 124: 212−222.
- Tienhaara A., Pulkki K., Mattila K. Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis. Br. J. of Haematolog. 1994- 86: 391−393.
- Togel F., Kroger N., Korioth F. Molecular methods for detection and quantification of myeloma cells after bone marrow transplantation: comparison between real-time quantitative and nested PCR. J. Hematol. Stem Cell Res. 2002- 11: 971−976.
- Tonegava S. Somatic generation of antibody diversity. Nature 1983- 302: 505−581.
- Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000- 355: 248−248.
- Tricot G., Sawyer J.R., Jahannath S. et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J. Clin. Oncol. 1997- 15: 2659−2666.
- Tricot G., Barlogie В., Jagannath S. Poor prognosis in Multiple Myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities Involving 11 q and not with other karyotype abnormalities. Blood 1995- 86: 4250−4256.
- Vacca A., Ribatti D., Roncali L., et al. Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Of Haematolog. 1994- 87: 503−508.
- Van Dongen J.J., Seriu Т., Panzer-Grumayer E.R., et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998- 28: 1731−1738.
- Vincent Т., Jourdan M., Sy M.S., et al. Hyaluronic acid induces survival and proliferration of human myeloma cells through an interleukin-6 mediated pathway the phosphotylation of retinoblastoma protein. J.Biol. Chem. 2001- 276: 1 472 814 736.
- Voena C., Ladetto M., Astolfi M. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B-cell tumors. Leukemia 1997- 11: 1793−1798.
- Westin K., Rodger S., Turesson I., et al. Interferon alpha-2b versus no maintenance therapy during the plateu phase in multiple myeloma. A randomized study. Br. J. Haematol. 1995- 89: 561.
- Wilson P. S., de Bouteiller O., Liu Y.J., et al. Somatic hypermutation introduces insertions and deletions into immunoglobulin V genes. J. Exp. Med. 1998- 187: 5970.
- Willems P., Verhagen O., Segeren C., et al. Consensus strategy to quantitative malignant cells in myeloma patients is validated in multicenter study. Blood 2000- 96: 63−70.
- Zandecki M. Multiple myeloma: Almost all patients are cytogenetically abnormal. Br. J. Haematol. 1996- 94: 217−227.
- Zhu P., Ma M., Yu J. Analysis of clonal origin of concomitant chronic lymphocytic leukemia and multiple myeloma in a patient with advanced age. Zhonghua Nei Ke Za Zhi. 1996- 35: 326−328 (abstr.).
- Zojer N., Konigsberg R., Ackermann J. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000- 95: 1925−1930.
- Yamada M., Hudson S., Tournay O. Detection of minimal disease in hematopoietic malignancies of B-cell lineage by using third-complementarity-determining region (CDR-lll-specific probes. Proc. Natl. Acad. Sci. USA. 1989- 86: 5123−5127.f